Hoth Therapeutics Secures Regulatory Approval for HT-001 Trial in Spain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Hoth Therapeutics announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER trial of HT-001, while concurrently reporting encouraging interim clinical results demonstrating meaningful efficacy and safety in cancer patients experiencing EGFR inhibitor-associated skin toxicities. The authorization supports the continued advancement of Hoth's randomized, placebo-controlled, dose-ranging Phase 2a study evaluating HT-001 for the treatment of dermatologic toxicities associated with epidermal growth factor receptor inhibitor therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
